StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Cumulative oncology & individualized neoantigen by Quarter

Cumulative oncology & individualized neoantigen therapy (mRNA-4157) trials (trials)

QuarterlyAnnual

Moderna Cumulative oncology & individualized neoantigen: 19.00 trials in Q2 2026, up 18.8% from a year earlier. That is the highest of the 34 quarters on record here.

Latest, Q2 2026
19.00
Period ended Jun 30, 2026
Change on a year earlier
+18.8%
16.00 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
1
ClinicalTrials.gov API v2 (ModernaTX, Inc.)

Where the Q2 2026 figure comes from

Source: ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗

Reported in ClinicalTrials.gov API v2 (ModernaTX, Inc.).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCumulative oncology & individualized neoantigen therapy (mRNA-4157) trials (trials)Year on yearSource
Q2 2026Jun 30, 202619.00+18.8%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2026Mar 31, 202618.00+20.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2025Dec 31, 202518.00+38.5%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2025Sep 30, 202517.00+41.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q2 2025Jun 30, 202516.00+33.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2025Mar 31, 202515.00+50.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2024Dec 31, 202413.00+44.4%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2024Sep 30, 202412.00+50.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q2 2024Jun 30, 202412.00+71.4%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2024Mar 31, 202410.00+42.9%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2023Dec 31, 20239.00+28.6%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2023Sep 30, 20238.00+14.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q2 2023Jun 30, 20237.00+16.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2023Mar 31, 20237.00+16.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2022Dec 31, 20227.00+16.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2022Sep 30, 20227.00+16.7%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗

Cite this data

StockData. (2026). Moderna Cumulative oncology & individualized neoantigen, quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ctgov-cum-oncology

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.